A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma

• 主要な著者: Renguo Guan (著者), Chengyou Yu (著者), Shaohua Li (著者), Jie Mei (著者), Wei Wei (著者), Rongping Guo (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background: Combination treatment with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has been widely used in patients with unresectable hepatocellular carcinoma (uHCC). As no standard guidelines exist for second-line therapy after failure of combination treatment, this st...